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Abstract For a long time, intraductal tumors of the pancreas
were neglected because they were misdiagnosed as mucin-
ous cystadenocarcinoma, ordinary ductal adenocarcinoma,
or chronic pancreatitis. Only in recent years have they been
recognized as clinical and pathological entities. Most
common are the intraductal papillary-mucinous neoplasms.
Although they show an adenoma-carcinoma sequence, they
have proved to have a more favorable prognosis than ductal
adenocarcinoma, when resected in a preinvasive state.
Recently, it has become clear that they constitute a
heterogeneous group with at least four subtypes. Their
stratification reveals that the various intraductal papillary-
mucinous neoplasm subtypes have different biological
properties with different prognostic implications.
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Historical notes and a rising incidence
The pancreatic tumors that are characterized by an intraductal
origin and growth pattern include intraductal papillary-
mucinous neoplasms [3, 24, 41], intraductal tubular carcino-
mas [22, 45], intraductal tubular adenomas of the pyloric
type [6], and intraductal acinar cell carcinomas [15]. Most
common are the intraductal papillary-mucinous neoplasms
(IPMNs). They are mucin-producing epithelial tumors that
usually show a papillary architecture and are associated with
dilatation of the ducts. Before 1990, these tumors were
thought to be rare. They first started to be recognized
approximately 20 years ago [31, 36, 39], when the many
different names given to the tumor in the 1980s were
replaced by the term IPMN [41]. This name was also
introduced in the classification of exocrine pancreatic tumors
propagated by the World Health Organization (WHO) [24]
and the fascicles of the Armed Forces Institute of Pathology
[44]. Since then, IPMNs have been reported with increasing
frequency (Table 1) and currently account for about 7% of
clinically diagnosed pancreatic neoplasms and up to 16% of
surgically resected pancreatic neoplasms and for almost 50%
of pancreatic cysts found incidentally [8, 17]. When only the
cystic tumors of the pancreas are considered, IPMNs take
first place, with a frequency of 24% [26].
The new incidence data on IPMNs raise the question
whether their increase in number is real or not. Of course, it
is difficult to accept that IPMNs might have been over-
looked in the past, not only clinically but also morpholog-
ically. There are good reasons, however, to believe that
IPMNs did always exist and did not really increase in
frequency. One reason is related to the rapid improvements
in modern imaging techniques, which enable more precise
recognition of cystic lesions, even if they are small and
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risk of pancreatic surgery. The most important fact,
however, may be that until 1999, the distinction between
IPMNs and mucinous cystic neoplasms (MCNs) was
unclear, so that many IPMNs were classified as MCNs
[50] or regarded as ductal adenocarcinomas or chronic
pancreatitis.
Adenoma-carcinoma sequence
In IPMNs, the normal ductal epithelium is replaced by
mucin-producing columnar cells showing papillary prolif-
erations and variable degrees of cellular atypia, even within
an individual neoplasm. They are graded according to the
most atypical area as IPMN with low grade dysplasia
(adenoma), IPMN with moderate dysplasia (borderline),
and IPMN with high grade dysplasia (carcinoma in situ).
An invasive component may be found in 38–50% of the
cases [7, 26, 40, 43]. Progression from adenoma to
carcinoma is estimated to occur at about 5 years [43].
IPMNs therefore provide a model of neoplastic progression
from a benign intraductal neoplasm through increasing
grades of dysplasia to invasive carcinoma.
Prognosis after resection
Between 80 and 90% of IPMNs are surgically resectable.
For these IPMNs, a 5-year survival rate of 77–100% was
reported, provided the tumors did not have an invasive
component (Table 2). By contrast, IPMNs with an invasive
component had a 3- to 5-year survival rate of only 36–46%
[12, 16, 43]( T a b l e2). Interestingly, the survival rate did not
appear to be dependent on the grade of dysplasia in the
IPMN if there was no invasive component [12, 16, 43, 47].
These data imply that the overall outcome of IPMNs
therefore largely depends on the presence of an invasive
component. If the tumor is already invasive, criteria for a
poor outcome are lymph node involvement, vascular
invasion, and bilirubin elevation [13]. A comparison of
the prognosis of all patients with invasive IPMNs with that
of patients with ductal adenocarcinoma reveals that patients
with IPMNs survive longer than those with ductal adeno-
carcinomas [29, 40, 43].
Several studies have reported recurrences after resec-
tion of noninvasive IPMNs, some of which revealed only
moderate dysplasia [12, 43, 47, 48]. The recurrences were
either local or metastatic (Table 2). To explain the
recurrences, particularly the local ones, it has to be
assumed that either tumor tissue was overlooked at the
pancreatic resection margin, or an invasive component
remained undetected in the resected specimen, or there
was multifocal disease. The last possibility has to be
considered if the surgical margins were negative and the
recurrence occurred in the pancreatic remnant. This has
been observed only in a few cases [40]. When metastatic
recurrences occur, it is most likely that they resulted from
inadequate sampling that failed to detect an invasive
component. Regarding the impact of a positive resection
margin on IPMN recurrence, it is interesting to note that it
has been reported that even IPMNs with positive margins
did not recur during a median follow-up period varying
from 19–40 months [13, 48]. The reason for this
phenomenon might be that the growth of the remaining
intraductal tumor tissue is so slow that clinical symptoms
Table 2 Five year survival rate and recurrence in 349
a intraductal
papillary-mucinous neoplasms
Noninvasive Invasive
77–100% 36–46%
No recurrence 93–98.7% 52–70%
Recurrence 1.3–7% 30–48%
Local up to 6% 8–48%
Distant (metastases) 1% 12%
Both 0% 10–48%
a[12, 43, 47]
Table 1 Incidence data on
intraductal papillary-mucinous
neoplasms
Author Period 1 Number of incidence Period 2 Number of incidence
Sohn et al. [43] 1987–2001 58 2001–2003 78
Wada et al. [47] 1988–2000 63 2001–2003 37
Our series 1981–2000 55 2001–2007 50
Table 3 Histopathological data on 105 intraductal papillary-mucinous
neoplasms collected during a period of 26 years
IPMN Gastric
(n=27)
(26%)
Intestinal
(n=57)
(54%)
Pancreatobiliary
(n=7)
(7%)
Oncocytic
(n=14)
(13%)
Noninvasive
(65%)
n=20
(74%)
n=35
(62%)
n=3
(43%)
n=10
(72%)
Adenoma 9 12 1 5
Borderline 7 18 2 1
Carcinoma
in situ
45 0 4
Invasive
(35%)
n=7
(26%)
n=22
(38%)
n=4
(57%)
n=4
(28%)
864 Virchows Arch (2007) 451:863–869only appear after a follow-up period of 2 to 3 years.
However, even if intraductal recurrences may take a long
time to become clinically apparent, a positive margin in
any IPMN case should lead to further tissue resection.
Histological type and prognosis
In 1991, it was reported that the invasive component of
IPMNs corresponded either to an ordinary ductal adeno-
Fig. 1 Histological subtypes of
intraductal papillary-mucinous
neoplasms of the pancreas and
their usual mucin pattern. a, b
IPMN of the intestinal type
positive for MUC2; c, d IPMN
of the pancreatobiliary type
positive for MUC1; e, f IPMN
of the oncocytic type showing
scattered positivity for MUC2;
g, h IPMN of the gastric type,
positive for MUC5
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(colloid) carcinoma [49]. This observation suggested that
IPMNs form a group of heterogeneous neoplasms. A
further argument for the heterogeneity of IPMNs was the
detection of IPMNs in branch ducts rather than in the main
duct, where most of the IPMNs are found. Finally, it was
recognized that IPMNs differ in their histological and
cytological features and in their mucin profile [3, 4, 18, 28,
32, 33]. Currently, four subtypes of IPMN can be
distinguished: an intestinal type, a pancreatobiliary type,
an oncocytic type, and a gastric type [18].
The most common type of IPMN is the intestinal type
(Table 3). It usually occurs in the main duct of the
pancreatic head [9] and shows a villous growth pattern
similar to that of villous adenoma in the colon. It also
expresses MUC2 and CDX2 but not MUC1 (Fig. 1a,b).
When this IPMN type becomes invasive, the invasive
component resembles mucinous (colloid) carcinoma [5,
28], a tumor of which at least 80% is composed of pools of
extracellular mucin containing single cells or strands of
neoplastic glandular epithelium or even a small component
of signet ring cells. Patients with colloid carcinoma have a
55% 5-year survival rate after resection [5]. These tumors
therefore seem to be much less aggressive than ordinary
ductal adenocarcinomas.
The pancreatobiliary type of IPMN is much rarer than
the intestinal type IPMN (Table 3). It shows complex
arborizing papillae and expresses MUC1 only (Fig. 1c,d).
Its invasive component usually corresponds to a conven-
tional ductal adenocarcinoma. The prognosis of this type of
IPMN, if invasive, seems to be similar to that of ductal
adenocarcinoma and therefore poorer than that of the
intestinal type of IPMN [4].
Fig. 2 IPMN of the gastric type
showing severe cellular atypia
and MUC5 positivity
Fig. 3 PanIN-1 lesion associated with lobular fibrosis
Fig. 4 Small multicystic duct-associated lesion in the periphery of
pancreatic tissue suggestive of an IPMN of the gastric type but
difficult to distinguish from a large PanIN-1 lesion
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oncocytic papillary neoplasm [2]) shows the same complex
papillae as the pancreatobiliary type, but the lining cells
reveal strongly eosinophilic cytoplasm. In addition, there
are often numerous goblet cells. The tumor cells express
MUC1 and MUC2 inconsistently (Fig. 1e,f). With fewer
than 20 cases reported in the literature to date [2, 20, 34, 35,
37, 38, 42], the clinical and pathological behavior of this
type is still unclear. Most of the cases (94%) were
diagnosed as carcinoma, some of them with an invasive
component or even distant metastases [37]. As the follow-
up in this patient group is very short, no relevant data are
available yet on survival and outcome.
The gastric type of IPMN exhibits papillary projections
lined by epithelial cells resembling gastric foveolar cells
and shows pyloric gland-like structures at the base of the
papillae. These cells express MUC5 (Fig. 1g,h), while
MUC1, MUC2, or CDX2 positivity is only occasionally
observed. The gastric type of IPMN corresponds to the
branch duct type, which occurs in the periphery of the
pancreatic parenchyma, most often in the uncinate process,
where it usually presents as a multicystic lesion with cysts
no larger than 3 cm [9]. The gastric type seems to be less
aggressive, i.e., less invasive, than the other IPMN subtypes
[10, 25, 33, 46] but may show severe cellular atypia in a
few cases (up to 25%) [46] (Table 3, Fig. 2) The size of the
lesion was unrelated to the grade of cellular atypia [46].
Interestingly, pancreatic intraepithelial neoplasia
(PanIN)-like complexes are frequently observed next to
gastric type IPMNs. This raises the question whether
IPMNs of the gastric type are a focal accentuation of a
diffuse disease rather than a localized lesion. They might
therefore also be related to the small peripheral cystic
changes described by Kimura et al. [21] in non-neoplastic
pancreata or the patchy lobular fibrosis associated with
PanIN-1B lesions described by Detlefsen et al. [14]
(Fig. 3). If this were the case, IPMNs of the gastric type
would actually be large PanIN-1 lesions. An argument for
this assumption is that both IPMNs of the gastric type and
PanIN-1 lesions stain for MUC5 in the absence of MUC1
and MUC2 positivity. This assumption would also explain
why it is difficult to distinguish PanIN lesions from some
IPMNs [27] (Fig. 4), despite a consensus definition of both
lesions [19].
Although the malignant potential of IPMNs of the
gastric type seems to be rather low, it has to be pointed
out that the fibrocystic changes that have been described in
pancreata removed from patients with a strong family
history of pancreatic cancer [11, 30] are similar, if not
identical, to IPMNs of the gastric type and their associated
PanIN lesions. This implies that IPMNs of the gastric type/
PanIN-1 lesions are not innocuous lesions but have a
malignant potential.
Summary and perspectives
The significance of IPMNs among the pancreatic tumors
has increased greatly in recent years because of their
improved recognition, both clinically and histopathologi-
cally and their much better prognosis than ordinary ductal
adenocarcinomas. Moreover, they appear to fall into four
subtypes that have special biological properties with
prognostic implications. Of particular interest in relation
to the development of ductal adenocarcinomas is the fact
that the so-called gastric type IPMNs seems to occur in
pancreata from patients with a strong family history of
pancreatic cancer. Furthermore, it is of interest that the
pancreatic IPMNs have their counterparts in IPMNs of the
biliary duct system, where the same subtypes may occur [1,
23, 51, 52]. The treatment of choice is resection, but future
trials may reveal that the extent of resection could depend
on the IPMN subtype.
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